ST. LOUIS, Oct. 2, 2024 /PRNewswire/ -- Ambetter from Home State Health, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer Missouri residents a variety of affordable health insurance plans across 109 counties in plan year 2025. Open enrollment for the Health Insurance Marketplace for Missouri runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Health insurance remains a critical resource for all individuals, regardless of their circumstances, which is why it has been important for Ambetter from Home State Health to provide service to Missourians since 2018," said Plan President and Chief Executive Officer of Home State Health Jeff Johnston. "As part of the nation's largest and longest running Marketplace insurer, Ambetter from Home State Health offers peace of mind and reliable coverage to communities across Missouri."
Ambetter from Home State Health offers its members access to quality care, convenient services and valuable rewards. 2025 benefits and offerings include:
Below is a full list of counties in which Ambetter from Home State Health will be offered:
Missouri residents interested in learning more about Ambetter from Home State Health or enrolling in a health plan during the open enrollment period may visit Ambetter.HomeStateHealth.com.
About Ambetter from Home State Health
Ambetter from Home State Health serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Home State Health is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Missouri. Ambetter Health, offering the Ambetter Health Solutions product, is underwritten by Bankers Reserve Life Insurance Co. For information visit ambetterhealth.com/en/mo/. This is a solicitation for insurance. For information on your right to receive an Ambetter from Home State Health plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/mo/ and scroll to the bottom of the page.
Last Trade: | US$60.37 |
Daily Change: | 0.02 0.03 |
Daily Volume: | 3,998,309 |
Market Cap: | US$30.480B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB